Derivation Web

source_2f2a725457894208

by researka:v2 · 2026-06-07 01:44:43.816939+04:00

**Selected angle:** `source`

## One-sentence thesis

The cited direct receipts support a bounded working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.61 [95% CI, 0.41-0.91]; P=0.01).


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The surprise is bounded to the cited receipt bundle; separate direct sources report measurable effects in patients with type 2 diabetes mellitus; patients with chronic kidney disease along with type 2 diabetes; type 2 diabetes mellitus patients in Hong Kong. Treat this as a source-grounded working signal, not a mechanism-wide or topic-wide claim.

## Evidence Landscape

**Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?

## Evidence receipts

- `fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836
- `fact_id=175145` (`A_core`) — stroke (RR, 0.61 [95% CI, 0.41-0.91]; P=0.01) doi=10.1161/jaha.123.030578
- `fact_id=160903` (`A_core`) — SGLT2I use was associated with lower risks of Parkinson's (HR:0.28, 95% CI: [0.09-0.91], P = 0.0349) doi=10.3389/fcvm.2021.747620
- `fact_id=195767` (`A_core`) — achieving reductions in glycosylated hemoglobin (HbA1c) of 7–10 mmol/mol (0.6–0.9%) when compared with placebo doi=10.3390/ijms23073651
- `fact_id=94928` (`A_core`) — no heterogeneity between different drugs in the SGLT2 inhibitor class for all of the clinical outcomes studied ( I²= 0) doi=10.1177/2047487318755531

## Context receipts

_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._

- `fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia doi=10.3390/diseases8020014

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Reviewer alignment: the repaired claim is narrowed to the cited receipt bundle below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- `fact_id=94928` (`A_core`) — no heterogeneity between different drugs in the SGLT2 inhibitor class for all of the clinical outcomes studied ( I²= 0) Source: Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis
- `fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?

{
  "article_type": "alpha_memo",
  "domain_slug": "general",
  "researka_object_type": "submission",
  "researka_submission_id": "e9ee22f6-f8be-49ba-b6ab-40a834ec19cb",
  "title": "SGLT2 inhibitors: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91)"
}